Sedivention raises €2.9M for one-time obesity treatment as Ozempic alternative

What's the deal? Sedivention, a medtech startup, has raised €2.9M in seed funding to develop a one-time treatment for obesity as an alternative to GLP-1 drugs like Ozempic. The round was led by BMP Ventures.

The company is building a minimally invasive procedure designed to offer lasting results without the need for ongoing injections or daily medication — a key pain point for patients on current weight-loss drugs.

Why now? The global obesity drug market is booming, driven by the massive success of GLP-1 receptor agonists from Novo Nordisk and Eli Lilly. But these drugs require continuous use to maintain results, and many patients regain weight once they stop. That creates a clear opening for a one-time intervention that could deliver permanent or long-lasting effects.

What could go wrong? Medtech devices face a long and expensive regulatory path. A one-time procedure must demonstrate not just safety and efficacy, but durable outcomes over years — a higher bar than a drug patients can simply stop taking. Competing against pharmaceutical giants with deep pockets and established distribution is no small challenge either.

The signal: Investor appetite is growing for alternatives to the GLP-1 drug paradigm. While Ozempic and Wegovy dominate headlines, the requirement for lifelong use and high costs have opened the door for surgical, device-based, and procedural competitors. Sedivention's raise signals that VCs see a viable market in durable, one-time obesity treatments — and that the next wave of innovation may come from medtech rather than pharma.

Read more: Tech Funding News